Celadon Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Celadon Pharmaceuticals has a total shareholder equity of £2.5M and total debt of £31.0K, which brings its debt-to-equity ratio to 1.3%. Its total assets and total liabilities are £8.5M and £6.0M respectively.
Belangrijke informatie
1.3%
Verhouding schuld/eigen vermogen
UK£31.00k
Schuld
| Rente dekkingsratio | n/a |
| Contant | UK£16.00k |
| Aandelen | UK£2.45m |
| Totaal verplichtingen | UK£6.01m |
| Totaal activa | UK£8.46m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: CEL's short term assets (£1.7M) exceed its short term liabilities (£878.0K).
Langlopende schulden: CEL's short term assets (£1.7M) do not cover its long term liabilities (£5.1M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: CEL's net debt to equity ratio (0.6%) is considered satisfactory.
Schuld verminderen: Insufficient data to determine if CEL's debt to equity ratio has reduced over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: CEL has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: CEL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.